Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 19/20 | 0.65 |
| ▸ | MMP13 | P45452 | 13/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP14 | P50281 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430701 | 1.00 | MMP12 (0.65) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6579319 | 1.00 | MMP12 (0.65) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6582450 | 0.98 | MMP12 (0.65) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6577228 | 0.98 | MMP12 (0.65) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6577328 | 0.97 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL7558734 | 0.97 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6579548 | 0.97 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6577251 | 0.89 | MMP13 (0.52) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6579753 | 0.89 | MMP13 (0.52) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6579654 | 0.87 | MMP13 (0.52) | MMP12MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | claimed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | claimed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| EP-1100792-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006561-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| US-6420408-B1 | MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, CARDIOVASCULAR DISORDERS, RESTENOSIS, PERIODONTAL DISEASE, AUTOIMMUNE OR INFLAMMATORY DISORDERS, ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, CEREBRAL AMYLOID ANGIOPATHY, | WARNER-LAMBERT COMPANY | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | MMP3, MMP12, MMP8 | MMP12 2/4885MMP13 6/4885MMP2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.